MagForce Nanotechnologies expands management team
To support 2011 product launch and further developments
The Berlin-based company said these new roles will support the launch of its EU-approved therapy for the treatment of brain tumours and the further development of its Nano-Cancer therapy in additional cancer indications.
Christoph Rehfuess joins MagForce as director of intellectual property. He is a European patent attorney with 12years of experience in the biotech intellectual property field at Medigene. He takes responsibility for patents, trademarks, and technical contracts.
Dirk Kautz takes the role of director of business/corporate development. Prior to joining MagForce, he worked for more than 13 years in the medical devices industry, holding management positions in marketing and corporate development at, among others, Nihon Kohden and Biotronik.
Kajo Wiest joins as director of finance and controlling and brings with him more than 10 years of finance and controlling experience at Jerini.
Stacy Wiedenmann becomes director of investor relations and corporate communications and brings with her over 10 years of experience. She has also worked at Jerini.
The fifth new recruit is Hans Joachim Hutt, who will support the company in the area of medical affairs. The firm said his medical training and more than 20 years of experience at pharmaceutical companies, including Boehringer Ingelheim, Sanofi, Bristol-Myers Squibb, and Sanofi Pasteur MSD, will help MagForce establish commercial networks and expand its therapeutic applications.
‘Filling these key company positions is an important step in the transformation of the company from a research and development only business into a commercial company. Additional hiring for the sales and marketing team will be completed by the end of the year,’ said Peter Heinrich, ceo of MagForce.
You may also like
Regulatory
MoonLake Immunotherapeutics faces Securities Class Action after disastrous Phase III trial results
The announcement about the trial results for the product candidate sonelokimab, a highly anticipated treatment for patients with skin disease, saw MoonLake investors' shares fall by about 90%, prompting an investigation into whether or not they were misled
Manufacturing
Roquette opens pharmaceutical innovation centre in Brazil
The Health & Pharma Solutions facility in São Paolo offers state-of-the-art laboratories for customers, with the Northeast Center for Strategic Technologies partnering with Roquette to empower young women to pursue careers in science through the Futuras Cientistas programme at the facility
Manufacturing
Samsung Bioepis and Phrontline join forces to advance best-in-class antibody-drug conjugate therapeutics for solid tumours
The pair will co-develop two investigational ADC assets directed against targets expressed in a broad range of cancers, adding a new class of bispecific and dual-payload ADC therapeutics to Samsung Bioepis' oncology portfolio
Research & Development
AlzeCure Pharma publishes response letter clarifying Alzstatin’s distinct mechanism in Alzheimer’s treatment
AlzeCure Pharma and leading academic collaborators have published a response in JPET addressing recent commentary on Alzstatin’s γ-secretase modulation data, reaffirming the promise of lead candidate ACD680 in Alzheimer’s therapy